New ACC/AHA lipid update explains PREVENT risk equations, updated thresholds, and when to start statins or CAC scoring to prevent heart attacks.
Back
Behind the Guidelines: Understanding 2026 ACC/AHA Dyslipidemia Guidelines
A 9-part series breaking down key questions and changes to the 2026 ACC/AHA Dyslipidemia guidelines, featuring Ann Marie Navar, MD, PhD, a writing committee member, and Pamela Morris, MD, vice chair of the writing committee.
Behind the Guidelines: Understanding 2026 ACC/AHA Dyslipidemia Guidelines
Episodes
All
All
EP. 2: Understanding the 2026 Dyslipidemia Guidelines: CAC Scoring, Risk Enhancers, & Incidental CAC
New guidance shows how risk enhancers and coronary calcium scores refine statin decisions, including handling incidental CAC on routine CT scans.
New US guidance spotlights one-time lipoprotein(a) tests and ApoB targets to uncover hidden heart risk and fine-tune lipid therapy.
New lipid guidance brings back LDL targets by risk, pairing percent reduction with absolute goals—and explains why lower is better.
New lipid guidelines sharpen LDL goals for diabetes, HIV, CKD, cancer survivors and seniors, highlighting statins’ power and shared decisions.
Trials show most heart supplements don’t lower LDL or prevent events; learn why omega‑3s, vitamins and red yeast rice fall short of statins.
New dyslipidemia guidance sets LDL targets for FH, urges genetic testing, and highlights evinacumab and APOC3 drugs for severe triglycerides.
New dyslipidemia guidance sharpens risk with CAC, checks lipoprotein(a), and targets LDL goals using expanded therapies for prevention.
Advertisement
Advertisement